MedTrace Logo

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

NCT05372003 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2024-02-26

No results posted yet for this study

Summary

The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils, their secreted cytokines (interleukin-4), and metabolism in human health and disease states such as obesity and insulin resistance.

Conditions

Interventions

DRUG

Dupilumab

dupilumab injections will be prescribed and managed by dermatology as standard of care

OTHER

Photo therapy

light therapy will be prescribed and managed by dermatology as standard of care

Sponsors & Collaborators

Principal Investigators

  • Elena Anna De Filippis, MD, PhD · Mayo

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-09
Primary Completion
2024-02-23
Completion
2024-02-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05372003 on ClinicalTrials.gov